Woodline discloses 7.5% Tango Therapeutics (TNGX) stake in 13G/A

Rhea-AI Filing Summary

Woodline Partners LP filed an amended beneficial ownership report showing a significant passive stake in Tango Therapeutics, Inc.. Woodline reports beneficial ownership of 10,072,225 shares of Tango common stock, representing 7.5% of the class.

The percentage is calculated using 134,677,094 shares of common stock outstanding as of November 1, 2025, as disclosed in a company registration statement. Woodline, a Delaware investment adviser, reports sole voting and dispositive power over these shares, which are directly held by Woodline Master Fund LP.

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics. Woodline Master Fund has the right to receive dividends and sale proceeds from more than 5% of the common stock.

Insights

Equity ownership and regulatory filings analyst

Woodline reports a 7.5% passive stake in Tango, a routine but notable ownership disclosure.

Woodline Partners LP, an investment adviser, reports beneficial ownership of 10,072,225 shares of Tango Therapeutics common stock, equal to 7.5% of the company’s outstanding shares based on 134,677,094 shares outstanding as of November 1, 2025. Woodline has sole voting and dispositive power over this position, which is held through Woodline Master Fund LP.

The filing uses the passive ownership framework, with Woodline certifying that the securities are held in the ordinary course of business and not to change or influence control of Tango. This positions Woodline as a large institutional holder rather than an activist. The Woodline Fund has the right to receive dividends and proceeds from the sale of more than 5% of the common stock, so economic exposure is concentrated there.

This type of Schedule 13G/A is typically administrative and does not, by itself, signal a change in corporate strategy or capital structure. Future ownership updates, if any, would appear in subsequent beneficial ownership reports or company filings as share counts or holder concentrations change over time.

FAQ

What ownership stake does Woodline Partners report in Tango Therapeutics (TNGX)?

Woodline Partners reports beneficial ownership of 10,072,225 shares of Tango Therapeutics common stock, representing 7.5% of the outstanding class. This stake is based on 134,677,094 Tango shares outstanding as of November 1, 2025, as disclosed in a company registration statement.

How did Woodline Partners calculate its 7.5% ownership of Tango Therapeutics (TNGX)?

The 7.5% figure is calculated using 10,072,225 Tango shares beneficially owned by Woodline compared with 134,677,094 shares of common stock outstanding. The outstanding share count comes from Tango’s Form S-3 registration statement dated November 21, 2025, which reports shares outstanding as of November 1, 2025.

Is Woodline Partners’ 7.5% Tango Therapeutics (TNGX) position passive or activist?

Woodline certifies the Tango stake is held in the ordinary course of business and not for the purpose of changing or influencing control. The filing states the securities were not acquired and are not held in connection with any transaction intended to affect control of the issuer.

Who actually holds the Tango Therapeutics (TNGX) shares reported by Woodline Partners?

The common stock is directly held by Woodline Master Fund LP. Woodline Partners LP, a Delaware limited partnership, is the investment adviser to the fund and reports sole voting and dispositive power over 10,072,225 Tango shares on behalf of the Woodline Fund.

What rights does Woodline Master Fund have regarding Tango Therapeutics (TNGX) shares?

Woodline Master Fund has the right to receive, or direct the receipt of, dividends and proceeds from the sale of more than 5% of Tango’s common stock. This reflects the fund’s economic interest in the shares for which Woodline Partners reports beneficial ownership.

What type of reporting entity is Woodline Partners in this Tango Therapeutics (TNGX) filing?

Woodline Partners is identified as an investment adviser organized as a Delaware limited partnership. It files the ownership report in that capacity, indicating it qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E) for purposes of beneficial ownership reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 03:22 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

87583X109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87583X109

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,072,225.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,072,225.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,072,225.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tango Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Brookline Avenue, Suite 901, Boston, MA 02215
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 134,677,094 shares of Common Stock outstanding as of November 1, 2025, as reported in the Company's Registration Statement on Form S-3, filed with the Securities and Exchange Commission on November 21, 2025.
(b)	Percent of class: 7.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	02/17/2026